Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | AKT2 | P31751 | 3/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719193 | 1.00 | AKT1 (0.44) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL3719200 | 1.00 | AKT1 (0.44) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL11961245 | 1.00 | AKT1 (0.44) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL11961825 | 0.94 | AKT1 (0.37) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL27902769 | 0.87 | MAPK1 (0.35) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL3732907 | 0.86 | AKT1 (0.48) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL3732905 | 0.86 | AKT1 (0.48) | AKT1AKT2AKT3SLC6A3SLC6A2 | |
| SCHEMBL3739689 | 0.82 | PIK3CD (0.39) | LMNA | |
| SCHEMBL3739679 | 0.82 | PIK3CD (0.39) | LMNA | |
| SCHEMBL3739683 | 0.82 | PIK3CD (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372842-B2 | Pyrazolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2242757-B1 | PYRAZOLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20100280043-A1 | PYRAZOLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2242757-A1 | PYRAZOLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089359-A1 | PYRAZOLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280043-A1 | PYRAZOLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | AKT1 567/4885AKT2 594/4885AKT3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.